护城河对比

The 10-K names Broadcom, Marvell and Astera Labs as principal competitors that compete on 'some, but not all' of Credo's solutions, and discloses that the top 10 customers were approximately 90% of fiscal 2026 revenue with two customers at 10% or more each. A defensible technical position sold into a handful of buyers with that much leverage is narrow, not wide.

来源：sec.gov

The FY2026 10-K shows a real, durable lock but not an unassailable one. On the durable side: "Our cloud storage services are based on the same ONTAP data management software that underpins our on-premises ONTAP storage infrastructure offerings", and the same filing's income statement shows the company holding a gross margin near 71% across all three reported years - $4,433M on $6,268M in FY2024, $4,613M on $6,572M in FY2025 and $4,899M on $6,925M in FY2026 - while revenue grew from $6,268M to $6,925M and income from operations widened from 19% to 24% of net revenues. Holding that margin through the memory-cost shock the same filing discloses is the commercial evidence the lock is worth something. On the limiting side, the filing says competition "is intense", that in public cloud "customers may choose native cloud services that are consumed as operating expenses", and that "New competitors or alliances among existing competitors could emerge and quickly gain significant market share" - and IDC's 1Q26 external-storage tracker (Blocks & Files, 2026-06-16, cited on the AFF/ASA product row below) ranks NetApp second behind Dell, not first.

来源：sec.gov

Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K.

来源：sec.gov

The filing states the products 'are based on our own optimized Serializer/Deserializer (SerDes) and Digital Signal Processor (DSP) technologies' and lists 'extent of IP protection and enforcement of rights' among the principal competitive factors in its market.

来源：sec.gov

The FY2026 10-K makes the source of the advantage explicit and it is the cost of leaving the data-management layer, not a network or a patent estate. The same ONTAP software runs the on-premises arrays and the cloud services ("Our cloud storage services are based on the same ONTAP data management software that underpins our on-premises ONTAP storage infrastructure offerings"), and the AFF family "allows customers to connect to clouds for more data services, data tiering, caching, and disaster recovery". A customer's volume layout, snapshot and replication workflow and operating tools therefore carry from the array into Azure, AWS and Google rather than being abandoned at the cloud boundary — the filing describes NetApp as "the only provider of enterprise-grade storage services natively embedded in the world's largest public cloud providers", so the usual moment of escape is instead the moment the relationship renews.

来源：sec.gov

Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly.

来源：sec.gov

The 10-K states 'We believe we are the only company in our industry offering a complete suite of high-performance connectivity solutions', while naming Broadcom, Marvell and Astera as principal competitors on parts of the portfolio — a co-leader's claim, attributed to the company, not an independently observed share.

来源：sec.gov

IDC's 1Q26 external enterprise storage systems tracker, as reported by Blocks & Files on 2026-06-16 (cited in full on the AFF/ASA product row below), ranks NetApp second worldwide behind Dell and ahead of Everpure, Huawei and HPE, attributing the placing to "its growing all-flash business and cloud-integrated data management". Second of five ranked vendors, in a market whose leader is someone else, is a shared front rank rather than an owned one - and the distinct claim NetApp makes in the FY2026 10-K is positional rather than volumetric: being "the only provider of enterprise-grade storage services natively embedded in the world's largest public cloud providers".

来源：sec.gov

Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K.

来源：sec.gov

The n-1 node advantage the filing describes lets Credo price against competitors from a lower cost base, but the same filing discloses two customers at 10% or more of revenue and a top-10 concentration near 90%, which is buyer leverage working the other way.

来源：sec.gov

It holds price rather than raising it. On the figures filed with the FY2026 10-K, gross margin was 70.7% of revenue in FY2024 ($4,433M on $6,268M), 70.2% in FY2025 ($4,613M on $6,572M) and 70.7% in FY2026 ($4,899M on $6,925M) - flat across three years in which revenue grew from $6,268M to $6,925M - and it held that level while absorbing a component-cost shock. It is no stronger than that because the filing's own risk factor lists "competitive pricing, customer price sensitivity" and "pricing and discounting pressures" among the drivers of gross margin, and discloses that the company "experienced inflationary pressure and supply chain constraints beginning in the second half of fiscal 2026, resulting in increased costs for memory and other components, which have affected our gross margins" - a cost shock it is absorbing rather than fully passing on.

来源：sec.gov

Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong.

来源：sec.gov

Upstream interconnect supplier: SerDes/DSP silicon and active cables sitting between accelerators, switches and optics inside AI data centers.

NetApp sits between the memory supply and the enterprise data centre. Upstream, the FY2026 10-K says "Third-party component costs make up a significant portion of our product costs" and singles out NAND as hard to manage "if supplies of certain components, including NAND, become limited relative to demand". Downstream, the hyperscalers are channel, partner and rival at once: the filing states "We both partner with and compete against cloud service providers through our cloud-based software and services offerings", while Azure NetApp Files, Amazon FSx for NetApp ONTAP and Google Cloud NetApp Volumes are delivered as those clouds' own natively embedded services. Distribution is a mix of direct sales and "an ecosystem of partners, including the leading cloud providers".

Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect.

• Optical PAM4 DSPs 前三 · 中等 来源：sec.gov
• PCIe Retimers 挑战者 · 中等 来源：sec.gov
• SerDes Chiplets and SerDes IP licensing 细分市场 · 深 来源：sec.gov
• ZeroFlap Active Electrical Cables (AECs) 领先 · 深 来源：sec.gov
• ZeroFlap Optical Transceivers 挑战者 · 中等 来源：sec.gov

• AFF and ASA all-flash storage arrays 前三 · 中等 来源：blocksandfiles.com
• Amazon FSx for NetApp ONTAP 领先 · 深 来源：docs.aws.amazon.com
• Azure NetApp Files 领先 · 深 来源：learn.microsoft.com
• NetApp AFX and AI Data Engine 挑战者 · 中等 来源：sec.gov
• NetApp Keystone 挑战者 · 中等 来源：sec.gov
• NetApp StorageGRID 细分市场 · 低 来源：sec.gov

• Mounjaro (tirzepatide) 前三 · 深 来源：sec.gov
• Verzenio (abemaciclib) 领先 · 中等 来源：living.tech
• Zepbound (tirzepatide) 领先 · 深 来源：sec.gov

编辑先验，未经回测。

查看它究竟如何投票 →

编辑先验，未经回测。

查看它究竟如何投票 →

编辑先验，未经回测。

查看它究竟如何投票 →